Skip to main content

Media Category: Management

Generics and biosimilars in Multiple Sclerosis: understanding efficacy, safety and clinical confidence

Written by ParadigMS Foundation on .

Generics and biosimilars are becoming increasingly relevant in Multiple Sclerosis (MS) care as more follow-on treatments enter clinical practice. In this keynote, Thomas Berger explains how generics and biosimilars differ, how they are evaluated and approved, and why regulatory quality, bioequivalence, immunogenicity and pharmacovigilance are central to confidence in their use. Key Insights from the Lecture: Generics and biosimilars are already established in other areas of neurology, but their use in Multiple Sclerosis remains relatively recent. A major concern among both...

Continue reading

New diagnostic criteria in MS: The evolving role of biomarkers in Multiple Sclerosis

Written by ParadigMS Foundation on .

This expert panel discussion explores the current challenges in understanding and managing neuromyelitis optica spectrum disorder (NMOSD). Bringing together clinical perspectives, the conversation highlights gaps in pathophysiology, limitations in monitoring tools, and ongoing uncertainties in long-term treatment strategies. Despite advances in biomarkers and therapies, real-world decision-making remains largely driven by clinical experience. Key Insights from the Lecture: Neurofilaments and GFAP are not specific to Multiple Sclerosis and should not replace established diagnostic...

Continue reading

Magd Zakaria: Prognostic Factors in Multiple Sclerosis: Supporting Early Treatment Decisions

Written by ParadigMS Foundation on .

Watch the interview Selecting the most appropriate treatment at diagnosis requires an accurate assessment of disease activity and prognosis. In this interview, Magd Zakaria discusses a practical scoring system that combines demographic, clinical and MRI characteristics to help stratify treatment-naïve patients according to their risk of disease progression and support informed therapeutic decisions. Key points discussed include: Why prognostic assessment remains essential when selecting an initial treatment strategy. The development of a practical scoring system based...

Continue reading

Early intervention in Multiple Sclerosis: the role of high-efficacy therapies in long-term outcomes

Written by ParadigMS Foundation on .

The treatment landscape for Multiple Sclerosis has expanded considerably, providing clinicians with a growing range of disease-modifying therapies. However, an important question remains: should treatment begin with a moderate-efficacy therapy and escalate when disease activity occurs, or should high-efficacy treatment be introduced earlier? This webinar examines the evidence behind both strategies, with a particular focus on the window of opportunity available during the early stages of Multiple Sclerosis. The speakers review how early intervention may influence relapse activity, disability...

Continue reading

Long-term Efficacy and Safety of Anti-CD20 Therapies

Written by ParadigMS Foundation on .

Anti-CD20 therapies have transformed the treatment landscape of Multiple Sclerosis (MS), offering highly effective disease control through targeted B-cell depletion. As these therapies are increasingly used early in the disease course and maintained over many years, understanding their long-term efficacy, safety, and optimal use has become essential for clinical practice. In this webinar, Celia Oreja-Guevara and Patrick Vermersch review the latest evidence on anti-CD20 therapies, including ocrelizumab, ofatumumab, rituximab, and ublituximab. Drawing from pivotal clinical trials, extension...

Continue reading

NMOSD Panel Discussion: Pathophysiology, Monitoring, and Treatment Challenges

Written by ParadigMS Foundation on .

This expert panel discussion explores the current challenges in understanding and managing neuromyelitis optica spectrum disorder (NMOSD). Bringing together clinical perspectives, the conversation highlights gaps in pathophysiology, limitations in monitoring tools, and ongoing uncertainties in long-term treatment strategies. Despite advances in biomarkers and therapies, real-world decision-making remains largely driven by clinical experience. Key Insights from the Lecture: Antibodies alone are not sufficient to cause disease Clinical context remains essential T cells play a...

Continue reading

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.